By Olivia Bugault

 

Merck KGaA said Monday that two of its CRISPR-Cas9-assisted genome-editing patents have been granted in the U.S.

The pharmaceutical company is in talks to license its technology that will support scientists and researchers in the development of therapies for difficult-to-treat diseases, it said. The two patents have been granted for its CRISPR-Cas9 cleavage and integration technology.

"The company has CRISPR patents granted in Australia, Canada, China, Europe, Israel, Singapore and South Korea with related patent filings in Brazil, India and Japan," Merck KGaA said.

CRISPR-Cas 9 is a technology that edit parts of the genome.

 

Write to Olivia Bugault at olivia.bugault@wsj.com

 

(END) Dow Jones Newswires

May 11, 2020 09:45 ET (13:45 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.